These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 30775841)

  • 21. Synergistic cytokine effects as apremilast response predictors in patients with psoriasis.
    Garcet S; Nograles K; Correa da Rosa J; Schafer PH; Krueger JG
    J Allergy Clin Immunol; 2018 Sep; 142(3):1010-1013.e6. PubMed ID: 29936103
    [No Abstract]   [Full Text] [Related]  

  • 22. Drug survival of apremilast in patients treated for psoriasis in a real-world setting.
    Lee EB; Amin M; Wu JJ
    J Am Acad Dermatol; 2018 Oct; 79(4):760-761. PubMed ID: 29588246
    [No Abstract]   [Full Text] [Related]  

  • 23. Apremilast and adalimumab: a novel combination therapy for recalcitrant psoriasis.
    Danesh MJ; Beroukhim K; Nguyen C; Levin E; Koo J
    Dermatol Online J; 2015 Jun; 21(6):. PubMed ID: 26158370
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Cytarabine and hematopoietic cell transplantation for mantle cell lymphoma. Analysis of 20 patients].
    Campbell J; Hurtado S; Kutz C; Soto K; Ernst D
    Rev Med Chil; 2019; 147(1):9-17. PubMed ID: 30848759
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bone marrow stromal cell-mediated degradation of CD20 leads to primary rituximab resistance in mantle cell lymphoma.
    Kuroda Y; Yashima-Abo A; Koyama D; Kikuchi J; Mori S; Ito S; Furukawa Y
    Leukemia; 2021 May; 35(5):1506-1510. PubMed ID: 32929128
    [No Abstract]   [Full Text] [Related]  

  • 26. A comparison of apremilast monotherapy and combination therapy for plaque psoriasis in clinical practice: A Canadian multicenter retrospective study.
    Ighani A; Georgakopoulos JR; Walsh S; Shear NH; Yeung J
    J Am Acad Dermatol; 2018 Mar; 78(3):623-626. PubMed ID: 28989112
    [No Abstract]   [Full Text] [Related]  

  • 27. European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC.
    Nast A; Spuls PI; van der Kraaij G; Gisondi P; Paul C; Ormerod AD; Saiag P; Smith CH; Dauden E; de Jong EM; Feist E; Jobling R; Maccarone M; Mrowietz U; Papp KA; Reich K; Rosumeck S; Talme T; Thio HB; van de Kerkhof P; Werner RN; Dressler C
    J Eur Acad Dermatol Venereol; 2017 Dec; 31(12):1951-1963. PubMed ID: 28895202
    [No Abstract]   [Full Text] [Related]  

  • 28. Real-World Experience With Apremilast in Treating Psoriasis.
    Mayba JN; Gooderham MJ
    J Cutan Med Surg; 2017; 21(2):145-151. PubMed ID: 27846617
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-world data on the efficacy and safety of apremilast in Japanese patients with plaque psoriasis.
    Ohata C; Ohyama B; Kuwahara F; Katayama E; Nakama T
    J Dermatolog Treat; 2019 Jun; 30(4):383-386. PubMed ID: 30221571
    [No Abstract]   [Full Text] [Related]  

  • 30. ▼ Apremilast for psoriasis and psoriatic arthritis.
    Drug Ther Bull; 2015 Sep; 53(9):105-8. PubMed ID: 26358317
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is rituximab retro in mantle cell lymphoma?
    Ryan CE; Cohen JB
    Blood; 2024 Jul; 144(3):241-243. PubMed ID: 39023870
    [No Abstract]   [Full Text] [Related]  

  • 32. Apremilast for the management of moderate to severe plaque psoriasis.
    Vangipuram R; Alikhan A
    Expert Rev Clin Pharmacol; 2017 Apr; 10(4):349-360. PubMed ID: 28276777
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast.
    Chiricozzi A; Caposiena D; Garofalo V; Cannizzaro MV; Chimenti S; Saraceno R
    Expert Rev Clin Immunol; 2016; 12(3):237-49. PubMed ID: 26692125
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Place of apremilast in the real-life treatment of patients with plaque psoriasis.
    Gisondi P; Geat D; Girolomoni G
    J Eur Acad Dermatol Venereol; 2021 Jan; 35(1):13. PubMed ID: 33617017
    [No Abstract]   [Full Text] [Related]  

  • 35. Treating moderate plaque psoriasis: prospective 6-month chart review of patients treated with apremilast.
    Knuckles MLF; Levi E; Soung J
    J Dermatolog Treat; 2019 Aug; 30(5):430-434. PubMed ID: 30339049
    [No Abstract]   [Full Text] [Related]  

  • 36. Viral encephalitis associated with rituximab maintenance therapy: two cases and a review of literature.
    Noij DP; den Heijer T; van Zaanen HCT
    Neth J Med; 2020 Feb; 78(1):37-40. PubMed ID: 32043478
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials.
    Thaçi D; Kimball A; Foley P; Poulin Y; Levi E; Chen R; Feldman SR
    J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):498-506. PubMed ID: 27538241
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.
    Ohtsuki M; Okubo Y; Komine M; Imafuku S; Day RM; Chen P; Petric R; Maroli A; Nemoto O
    J Dermatol; 2017 Aug; 44(8):873-884. PubMed ID: 28391657
    [TBL] [Abstract][Full Text] [Related]  

  • 39. VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study.
    Chang JE; Carmichael LL; Kim K; Peterson C; Yang DT; Traynor AM; Werndli JE; Huie MS; McFarland TA; Volk M; Blank J; Callander NS; Longo WL; Kahl BS
    Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):e61-e67. PubMed ID: 29191715
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study.
    Gottlieb AB; Matheson RT; Menter A; Leonardi CL; Day RM; Hu C; Schafer PH; Krueger JG
    J Drugs Dermatol; 2013 Aug; 12(8):888-97. PubMed ID: 23986162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.